Trialbee is pleased to announce that we are providing patient recruitment services to promote patient diversity for vaccine trials investigating the safety and efficacy of leading vaccine candidates against COVID-19 and funded by BARDA, part of the HHS Office of the Assistant Secretary for Preparedness and Response.
MALMÖ, SWEDEN and RESEARCH TRIANGLE PARK, NC — September 3, 2019 —
Trialbee announces strong sales results in H1 2019 and the launch of a 10 yearlong assignment for its engagement and retention technology with one of the largest global pharmaceutical companies.
Trialbee, a leading technology company in the development of innovative software to reduce clinical trial recruitment timelines and increase the patient engagement experience, announces the appointment of Richard Thomas as its new member to its Board of Directors.
Trialbee delivered strong YoY sales result for its patient matching and engagement technology and exceeded its H1 2019 sales target by 26%. The sales uptake in H1 2019 is predominately driven by growth within the pharmaceutical customer segment. H1 has also demonstrated an increased interest among some of the leading global Contract Research Organizations, a trend the company believes will continue to develop. Sales in H1 is also indicating that customers are requesting to onboard Trialbee’s technology earlier in the drug development process, which is in line with Trialbee’s sales strategy. The technology platform is gaining more momentum as an embedded solution from clinical trial planning through the patient retention phase.
“We are pleased to note that our solutions are delivering demonstrable recruitment and retention efficiencies for our customers, which has advanced Trialbee to become an embedded healthcare partner with major clients, a key strategic driver for continued double digit growth.” Robert Molander, Chief Commercial Officer at Trialbee, said.
In addition to the strong sales result in H1, Trialbee was also successful in landing its longest engagement and retention assignment with one of the largest pharmaceutical companies. Trialbee’s engagement technology will follow more than 3,000 subjects over a 10-year period to support timely and accurate monitoring of questionnaire completeness. The assignment demonstrates the potential of the technology and future applications, but also the high value it delivers to patients and sponsors in securing reliable long-term study outcomes.
Trialbee is a world leading technology provider in patient matching and engagement, empowering patients to participate in clinical trials as a care option. Founded in 2010, Trialbee has continuously innovated patient-centric technology solutions for global clinical trials. Trialbee – Dedicated to patients; driven by science; and powered by data. For more information, visit trialbee.com and contact us at [email protected]
+46(0)76-525 82 11
Executive Chairman Trialbee